Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.46 |
| ▸ | KDM1A | O60341 | 3/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 5/20 | 0.41 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.38 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.37 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.35 |
| ▸ | MMP1 | P03956 | 1/20 | 0.35 |
| ▸ | MMP2 | P08253 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1670147 | 1.00 | KCNH2 (0.46) | KCNH2KDM1AHDAC8HDAC6GPR119 | |
| SCHEMBL13277597 | 0.92 | MAOB (0.48) | KCNH2KDM1AHDAC8HDAC6GPR119 | |
| SCHEMBL13277598 | 0.92 | MAOB (0.48) | KCNH2KDM1AHDAC8HDAC6GPR119 | |
| SCHEMBL13277048 | 0.77 | RAB9A (0.47) | KCNH2GPR119RAB9AMAOBSMPD1 | |
| SCHEMBL24890925 | 0.77 | KDM1A (0.43) | KCNH2KDM1AHDAC8HDAC6GPR119 | |
| SCHEMBL1667795 | 0.74 | RAB9A (0.48) | KCNH2RAB9AMAOBADAM17SMPD1 | |
| SCHEMBL2339013 | 0.74 | KDM1A (0.58) | KDM1ARAB9AMAOB | |
| SCHEMBL1667517 | 0.73 | RAB9A (0.51) | KCNH2GPR119RAB9AMAOBADAM17 | |
| SCHEMBL1667828 | 0.71 | KCNH2 (0.56) | KCNH2KDM1ARAB9AMAOB | |
| SCHEMBL13469006 | 0.71 | KCNH2 (0.56) | KCNH2KDM1ARAB9AMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2486002-B1 | SUBSTITUTED HETEROARYL- AND ARYL- CYCLOPROPYLAMINE ACETAMIDES AND THEIR USE | ORYZON GENOMICS SA (ES) | 2019-03-27 | — | — | EP | disclosed |
| US-8946296-B2 | Substituted heteroaryl- and aryl-cyclopropylamine acetamides and their use | ORYZON GENOMICS S.A. (ES) | 2015-02-03 | — | — | US | disclosed |
| US-20120264823-A1 | SUBSTITUTED HETEROARYL- AND ARYL-CYCLOPROPYLAMINE ACETAMIDES AND THEIR USE | ORYZON GENOMICS S.A. | 2012-10-18 | — | — | US | disclosed |
| EP-2486002-A1 | SUBSTITUTED HETEROARYL- AND ARYL- CYCLOPROPYLAMINE ACETAMIDES AND THEIR USE | Oryzon Genomics, S.A. (ES) | 2012-08-15 | — | — | EP | disclosed |
| WO-2011042217-A1 | SUBSTITUTED HETEROARYL- AND ARYL- CYCLOPROPYLAMINE ACETAMIDES AND THEIR USE | ORYZON GENOMICS S.A. (ES) | 2011-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264823-A1 | SUBSTITUTED HETEROARYL- AND ARYL-CYCLOPROPYLAMINE ACETAMIDES AND THEIR USE | CBR1, CNR1, CBR3 | KCNH2 1511/4885KDM1A 877/4885HDAC8 3224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.